Several CCR5 antagonists, which inhibit the entry of HIV-1 in the host cell, have proven a valuable strategy for the treatment of AIDS. However, the virus can switch to the CXCR4 co-receptor to enter cells, thus prompting the need for CXCR4 antagonists.
In a review published in the January issue of Expert Opinion on Therapeutic Patents, Dr Liotta explores the preclinical development of such compounds, and finds that this relatively recent field could offer therapeutic options in several disease areas.
Showing posts with label CCR5. Show all posts
Showing posts with label CCR5. Show all posts
Wednesday, 15 October 2008
CXCR4 antogonists
Subscribe to:
Posts (Atom)